China-based HitGen Inc. (SHA: 688222) announced the establishment of a strategic partnership with compatriot firm Zhejiang Haichang Biotechnology Co., Ltd, an RNA interference (RNAi) specialist, to develop anti-cancer RNAi drugs. The partnership aims to leverage the strengths of both companies in RNAi drug discovery and delivery systems.
Company Profiles
HitGen, focused on the discovery and optimization of RNAi drugs, has a core technology platform for RNAi drug research and development. The company integrates the entire technology chain, including RNA sequence design (including chemical modification), synthesis, off-target effect prediction, and biological function evaluation. HitGen will utilize its technical expertise and CRO platform advantages to design, screen, and evaluate effective siRNA / saRNA sequences for customers.
Zhejiang Haichang Biotechnology Co., Ltd (Haichang Bio) boasts the QTsome delivery platform, which holds global intellectual property rights. RNAi drugs, as a new type of drug molecular entity, can directly and precisely target RNA, fundamentally and highly selectively modulating the expression level of pathogenic proteins to achieve better disease treatment effects. The successful development of RNAi drugs requires highly optimized small nucleic acid sequences and efficient delivery systems.
Partnership Details
The partnership between HitGen and Haichang Bio will combine their respective strengths in RNAi drug discovery and RNAi delivery systems. This collaboration aims to develop effective RNAi drugs for cancer treatment, benefiting patients in China and beyond.-Fineline Info & Tech
